Redeye takes a positive stance towards CombinedX's acquisition of the Microsoft-focused CRM speciali...
Suominen has initiated a consultation process to close manufacturing at its Mozzate plant in Italy i...
Redeye updates its outlook on Calliditas, anticipating US launch support and the European launch ove...
Q4 report due on Monday, 23 January Discontinues unprofitable operations, '23e-'24e EBITA up 2% 11x...
Redeye comments on Genovis following today's news regarding a sublicensing of Xork to Astellas Pharm...
Redeye revisits its view of Herantis in the wake of the company’s shifted strategy toward HER-096– a...
Utfall av företrädesemissionen Bolaget meddelade under veckan utfallet i företrädesemissionen som av...
During the quarter, Audientes expanded its network of collaboration partners, and the company have i...
Redeye embraces the FDA Fast Track Designation for the evaluation process of Sedana Medical’s soluti...
Redeye is encouraged by the continuous positive news flow related to Catalyst, and we embrace the ju...
Endomines reported high-grade drill results significantly below the current production level.
Redeye has revisited our case after the announced Telia framework agreement.
Redeye comments on Freemelt’s new order wins and update its estimates for Q4 2022e once again.
Redeye ceases its coverage of aXichem due to the end of the contractual period.
Episurf recently announced that it has received its first product clearance for use on the US market...
Redeye considers Mitazalimab’s results in the first interim readout of the phase II trial presented ...
Redeye comments on Sensys Gatso’s recent large orders for its managed-services business.
Redeye is encouraged by the FDA approval for Episurf Medical’s patellofemoral system product and arg...
Insurtechbolaget Paydrives intäkter ökade till 6,1 (4,4) miljoner kronor under det tredje kvartalet ...
Ascelia announced that 65 patients has now completed the SPARKLE study.
